Sentinel node biopsy from an immunological perspective: Premature optimism? (2);La biopsia del ganglio centinela desde una perspectiva inmunológica: ¿Optimismo prematuro?

Actas Dermo-Sifiliograficas

Volumn 94, Issue 1, 2003, Pages 60-62

  Pizarro, Ángel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC PROCEDURE; IMMUNOHISTOCHEMISTRY; LETTER; MELANOMA; MORTALITY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN METASTASIS; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR LOCALIZATION;

EID: 0037503820     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(03)79194-7     Document Type: Letter

References (20)

1. Lázaro P, Bittini A, Bueno C, Escat JL, Lecona M, Pérez S. Mapeo linfático y biopsia del ganglio centinela en el melanoma cutáneo. Actas Dermosifiliogr 2001;92:319-33.
2. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19:2851-5.
3. Coldiron B. Regarding sentinel node biopsy in the management of melanoma. Dermatol Surg 2001;27:95-7.
4. Thomas JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma. Its use should be confined to patients in clinical trials. Br Med J 2000;321:3-4.
5. Otley CC. Sentinel lymph node biopsy for melanoma. Standard of care? Dermatol Surg 2000;26:1067-9.
6. Dunn CL, Zitelli JA. Standards of care for patients with malignant melanoma. J Am Acad Dermatol 2000;43:155-6.
7. Morton DL, Ollila DW. Critical review of the sentinel node hypothesis. Surgery 1999;126:815-9.
8. Santin AD. Lymph node metastases. The importance of the microenvironment. Cancer 2000;88:175-9.
9. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
10. Harada M, Tamada K, Abe K, Li T, Onoe Y, Tada H, et al. Systemic administration of inteleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state. Int J Cancer 1998;75:400-5.
11. Szymanski MB, Ackerman AB. Sentinel lymph node biopsy? Dermatopathology Practical Conceptual 1998;4:253-7.
12. Shivers SC, Li W, Lin J, Stall A, Stafford M, Messina J, et al. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 2001;158:187-99.
13. Brownbridge GG, Gold J, Edward M, Mackie RM. Evaluation of the use of tyrosina-especific and melan A/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001;144:279-87.
14. Mori M, Mimori K, Ueo H, Karimine N, Barnard GF, Sugimachi K, et al. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int J Cancer 1996;68:739-43.
15. Kirkwood JM, Strawderman MH, Ernstott MS, Smith TJ, Borden EC, Blum RH, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7-17.
16. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff M, Richards J, Flaherty LE, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
17. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, Maczey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114;637-42.
18. Otley CC, Zitelli JA. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities. Dermatol Surg 2000;26:177-80.
19. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadyuvant. Cancer Res 2001;61:206-14.
20. Jonuleit H, Geisecke-Tuettenberg A, Tüting T, Thurner-Schuler B, Stuge TB, Paragnik L, et al. A comparison of two types of dendritic cell as adyuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-51.